Site content: Global

Press Release

A robust method to study cancer heterogeneity in liquid biopsy

Copy Number Alteration Profiling of Single Circulating Tumor Cells which May Be used to Predict Response to Therapy   Scientists reported the development of a robust and...

Top International Experts Gather to Understand the Many Faces of Cancer

Second World Summit on Cancer Heterogeneity and Precision Medicine Meets in Washington   WASHINGTON, D.C., May 11, 2017 – Cancer experts from around the world will...

Menarini-Silicon Biosystems Completes Acquisition of CELLSEARCH® Assets

Liquid Biopsy Test for Circulating Tumor Cells Marks Its First Entry into U.S. Diagnostics Market BOLOGNA, Italy, and Philadelphia, PA, April 3, 2017 – Menarini-Silicon...

Menarini-Silicon Biosystems to Acquire CELLSEARCH® CTC System

Only FDA-Cleared CTC test to join Company’s Portfolio of Diagnostics Bologna, Italy and San Diego, CA, Dec 20, 2016 - Menarini-Silicon Biosystems today announced they have...

DEPArray™ Single-Cell Isolation Technology Enables Researchers to Develop a Model for Predicting Response to Treatment in Patients with Lung Cancer

Genetic Profiles of Circulating Tumor Cells May Predict Drug Resistance and Clinical Outcomes   BOLOGNA, Italy, and SAN DIEGO, Calif., November 25, 2016 –...
12